Polymeric Biomaterials Market

The polymeric biomaterials market is expected to reach USD 16.93 billion by 2030 from the estimated USD 11.83 billion in 2025, at a CAGR of 7.4%. The growth of the polymeric biomaterials market is driven by the broad adoption across medical devices, drug delivery systems, tissue repair applications, and cost advantages compared to metallic and ceramic biomaterials in high-volume applications.

The key players in the polymeric biomaterials industry include BASF SE (Germany), Covestro AG (Germany), Celanese Corporation (US), DSM (Netherlands), Corbion NV (Netherlands), Evonik Industries AG (Germany), Victrex PLC (UK), and Noble Biomaterials (US), among others. Companies in this space are adopting expansion strategies to strengthen their global footprint and advance their technology portfolios. In March 2025, BASF SE introduced HySorb B 6610 ZeroPCF, the first polyacrylate-based superabsorbent polymer marketed with a product carbon footprint of zero, expanding its medical-grade SAP portfolio for advanced hygiene and wound-care applications while helping customers meet ambitious sustainability targets.?

To know about the assumptions considered for the study download the pdf brochure

BASF SE (Germany)

BASF offers medical-grade Ultraform PRO, Ultradur PRO, and Elastollan TPU that address demanding applications such as drug delivery, surgical instruments, and durable device housings. These polymers combine biocompatibility, sterilization resistance, and strong regulatory support, helping OEMs streamline approval processes and ensure consistent, long-term supply for critical medical technologies.

Covestro AG (Germany)

Covestro’s healthcare portfolio centers on Makrolon medical polycarbonate and other high-performance plastics designed for drug-delivery systems, respiratory equipment, and transparent monitoring components. These materials deliver clarity, toughness, chemical resistance, and repeated-sterilization capability, enabling thinner, safer, and more ergonomic devices while supporting robust compliance documentation for global regulatory submissions.

Celanese Corporation (US)

Celanese provides an extensive MT-series medical polymer range, including POM, PBT, UHMW-PE, and LCP for orthopedic implants, surgical tools, drug-delivery, and diagnostic housings. With established biocompatibility testing, master files, and change-control procedures, Celanese supports OEMs in managing lifecycle risk, ensuring material continuity, and accelerating market entry for sophisticated polymeric medical devices.

Market Ranking

The polymeric biomaterials market is highly consolidated, with a handful of large chemical and biomaterials suppliers defining technical and regulatory baselines for medical-grade polymers. BASF (Germany), Covestro AG (Germany), and Celanese Corporation (US) dominate medical plastics such as engineering thermoplastics and polycarbonates used in durable, sterilizable device components and drug-delivery systems. DSM (Netherlands) and Corbion (Netherlands) have products like bioresorbable side, providing lactic acid-based polymers and specialty resins for implants, controlled-release formulations, and tissue-engineering constructs. Together, these players combine extensive clinical track records, master-file support, and global GMP manufacturing, which helps device OEMs manage qualification risk, ensure long-term material continuity, and accelerate the adoption of new polymeric biomaterial solutions in high-value therapeutic areas.

Related Reports:

Polymeric Biomaterials Market by Type (Polymethylmethacrylate, Polyethylene, Polyester, Polyvinylchloride, Silicone Rubber, Nylon, Polyetheretherketone, Other Polymeric Biomaterials), Application (Orthopedic, Dental, CVD) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com